UCHL1 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 45 bp deletion in exon 1.
Images
Key facts
- Cell type
HEK-293T
- Species or organism
Human
- Tissue
Kidney
- Knockout validation
Sanger Sequencing, Western blot
Knockout achieved by using CRISPR/Cas9, Homozygous: 45 bp deletion in exon 1.
Alternative names
Epididymis luminal protein 117, Epididymis secretory protein Li 53, HEL 117, HEL S 53, NDGOA, Neuron cytoplasmic protein 9.5, OTTHUMP00000218137, OTTHUMP00000218139, OTTHUMP00000218140, OTTHUMP00000218141, PGP 9.5, PGP95, Park 5, Protein gene product 9.5, UCHL1_HUMAN, Ubiquitin C terminal esterase L1, Ubiquitin C terminal hydrolase, Ubiquitin C terminal hydrolase L1, Ubiquitin carboxyl terminal esterase L1, Ubiquitin carboxyl-terminal hydrolase isozyme L1, Ubiquitin thioesterase L1, Ubiquitin thiolesterase, Ubiquitin thiolesterase L1
What's included?
Recommended products
UCHL1 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 45 bp deletion in exon 1.
Alternative names
Epididymis luminal protein 117, Epididymis secretory protein Li 53, HEL 117, HEL S 53, NDGOA, Neuron cytoplasmic protein 9.5, OTTHUMP00000218137, OTTHUMP00000218139, OTTHUMP00000218140, OTTHUMP00000218141, PGP 9.5, PGP95, Park 5, Protein gene product 9.5, UCHL1_HUMAN, Ubiquitin C terminal esterase L1, Ubiquitin C terminal hydrolase, Ubiquitin C terminal hydrolase L1, Ubiquitin carboxyl terminal esterase L1, Ubiquitin carboxyl-terminal hydrolase isozyme L1, Ubiquitin thioesterase L1, Ubiquitin thiolesterase, Ubiquitin thiolesterase L1
Key facts
- Cell type
HEK-293T
- Species or organism
Human
- Tissue
Kidney
- Knockout validation
Sanger Sequencing, Western blot
- Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 45 bp deletion in exon 1.
- Concentration
Properties
- Gene name
UCHL1
- Gene editing type
Knockout
- Gene editing method
CRISPR technology
- Knockout validation
Sanger Sequencing, Western blot
- Zygosity
Homozygous
Quality control
- STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
EU: 2 US: 2
- Adherent/suspension
Adherent
- Gender
Female
Storage
- Shipped at conditions
Ambient - Can Ship with Ice
- Appropriate long-term storage conditions
-20°C
Notes
Knockout cell lysate achieved by CRISPR/Cas9.
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
Supplementary info
- Activity summary
Protein Gene Product 9.5 (PGP9.5) also known as ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) is an enzyme of approximately 27 kDa mass. PGP9.5 is highly expressed in neurons and neuroendocrine cells and is involved in the processing of ubiquitinated proteins. Ubiquitination and deubiquitination are critical for maintaining cellular protein homeostasis. PGP9.5 is present in the central and peripheral nervous systems. Researchers often utilize PGP9.5 as a neuronal marker due to its strong expression in nerve tissues. Antibody clone 13C4 is commonly used in PGP9.5 immunohistochemistry to visualize this protein in histopathology sections.
- Biological function summary
PGP9.5 plays a significant role in the ubiquitin-proteasome pathway where it regulates protein degradation. It functions by cleaving ubiquitin from ubiquitin-protein conjugates which can recycle ubiquitin for reuse impacting protein turnover. This process is important for removing misfolded or damaged proteins maintaining cellular integrity. PGP9.5 has not been documented as a part of any large multimeric complex; its action is rather individual yet vital in cellular processes.
- Pathways
PGP9.5 is an important participant in the ubiquitin-dependent proteolysis pathway. This pathway controls the degradation of proteins that regulate cell cycle differentiation and neuromodulation. PGP9.5 works in tandem with other proteins such as the proteasome complex to remove proteins tagged for destruction. Another important pathway linked with PGP9.5 is the neuronal development pathway in which its activity supports neuron growth and repair.
- Associated diseases and disorders
Defective PGP9.5 function associates mainly with neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. Mutations or dysregulation in PGP9.5 expression are implicated in the pathogenesis of these conditions affecting protein degradation and neuronal health. Other proteins like α-synuclein in Parkinson's disease interact with PGP9.5 pathways indicating their involvement in disease mechanisms. Researchers consider PGP9.5 a potential biomarker for neuronal pathology through methods like PGP9.5 IHC allowing for evaluation of nerve damage and neuroendocrine tumor diagnosis.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2 product images
Western blot - Human UCHL1 (PGP9.5) knockout HEK-293T cell lysate (ab263773)
Lane 1: Wild-type Hap1 cell lysate (20 μg)
Lane 2: UCHL1 knockout Hap1 cell lysate (20 μg)
Lane 3: SH-SY5Y cell lysate (20 μg)
Lane 4: Wild-type HEK-293T cell lysate (20 μg)
Lane 5: UCHL1 knockout HEK-293T cell lysate (20 μg)
Lanes 1 - 5: Merged signal (red and green). Green - Anti-PGP9.5 antibody [EPR4118] - Neuronal Marker ab108986 observed at 25 kDa. Red - loading control, Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-PGP9.5 antibody [EPR4118] - Neuronal Marker ab108986 was shown to react with PGP9.5 in wild-type HEK-293T cells. Loss of signal was observed when knockout cell line Human UCHL1 (PGP9.5) knockout HEK-293T cell line ab255443 (knockout cell lysate ab263773) was used. Wild-type and PGP9.5 knockout samples were subjected to SDS-PAGE. Anti-PGP9.5 antibody [EPR4118] - Neuronal Marker ab108986 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively.Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-PGP9.5 antibody [EPR4118] - Neuronal Marker (Anti-PGP9.5 antibody [EPR4118] - Neuronal Marker ab108986) at 1/1000 dilution
Lane 1: Wild-type HAP1 cell lysate at 20 µg
Lane 2: UCHL1 knockout HAP1 cell lysate at 20 µg
Lane 3: SH-SY5Y cell lysate at 20 µg
Lane 4: Wild-type HEK-293T cell lysate at 20 µg
Lane 5: UCHL1 knockout HEK-293T cell lysate at 20 µg
SecondaryAll lanes: Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) at 1/20000 dilution
Performed under reducing conditions.
Predicted band size: 24 kDa
Observed band size: 25 kDa, 37 kDa
Lanes 1 - 5: Merged signal (red and green). Green - Anti-PGP9.5 antibody [EPR4118] - Neuronal Marker ab108986 observed at 25 kDa. Red - loading control, Anti-GAPDH antibody [6C5] - Loading Control ab8245 observed at 37 kDa.
Anti-PGP9.5 antibody [EPR4118] - Neuronal Marker ab108986 was shown to react with PGP9.5 in wild-type HEK-293T cells. Loss of signal was observed when knockout cell line Human UCHL1 (PGP9.5) knockout HEK-293T cell line ab255443 (knockout cell lysate ab263773) was used. Wild-type and PGP9.5 knockout samples were subjected to SDS-PAGE. Anti-PGP9.5 antibody [EPR4118] - Neuronal Marker ab108986 and Anti-GAPDH antibody [6C5] - Loading Control (Anti-GAPDH antibody [6C5] - Loading Control ab8245) were incubated overnight at 4°C at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.
Sanger Sequencing - Human UCHL1 (PGP9.5) knockout HEK-293T cell lysate (ab263773)
Homozygous: 45 bp deletion in exon 1
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com